NCIC Clinical Trials Group experience of employing patient-reported outcomes in clinical trials: an illustrative study in a palliative setting

References

• Hearn J, Higginson IJ. Outcome measures in palliative care for advanced cancer patients: a review. J. Public Health Med.19(2), 193–199 (1997).
   PubMedGoogle Scholar
• Hughes R, Aspinal F, Addington-Hall J et al. Professionals’ views and experiences of using outcome measures in palliative care. Int. J. Palliat. Nurs.9(6), 234–238 (2003).
   PubMedGoogle Scholar
• Carson MG, Fitch MI, Vachon MLS. Measuring patient outcomes in palliative care: a reliability and validity study of the Support Team Assessment Schedule. Palliat. Med.14, 25–36 (2000).
   PubMedGoogle Scholar
• Stephens RJ, Hopwood P, Girling DJ. Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br. J. Cancer79(3–4), 538–544 (1999).
   PubMed Web of Science ®Google Scholar
• Porzsolt F, Tannock I. Goals of palliative cancer therapy. J. Clin. Oncol.11(2), 378–381 (1993).
   PubMedGoogle Scholar
• Shelley W. Measuring the benefit and toxicity of palliative radiotherapy. Can. J. Oncol.6(Suppl. 1), 86–89 (1996).
   PubMedGoogle Scholar
• Brundage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J. Natl Cancer Inst.85, 1138–1148 (1993).
   PubMed Web of Science ®Google Scholar
• Savage C, Pater J, Tu D, Norris B. He said/she said: how much agreement is there on symptoms between common toxicity criteria and quality of life? Proc. Annu. Meet. Am. Assoc. Cancer Res.21, 386 (2002) (Abstract 1540).
   Google Scholar
• [No authors listed]. Medical Research Council Lung Cancer Working Party. Randomized trial of four-drug versus less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Br. J. Cancer73, 406–413 (1996).
   PubMed Web of Science ®Google Scholar
• Collins TM, Ash DV, Close HJ, Thorogood J. An evaluation of the palliative role of radiotherapy in inoperable carcinoma of the bronchus. Clin. Radiol.39(3), 284–286 (1988).
   PubMedGoogle Scholar
• Ellis PA, Smith IE, Hardy JR et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br. J. Cancer71(2), 366–370 (1995).
   PubMed Web of Science ®Google Scholar
• Moore MJ, Osoba D, Murphy K et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J. Clin. Oncol.12(4), 689–694 (1994).
   PubMed Web of Science ®Google Scholar
• Ballinger AB, McHugh M, Catnach SM, Alstead EM, Clark ML. Symptom relief and quality of life after stenting for malignant bile duct obstruction. Gut35(4), 467–470 (1994).
   PubMedGoogle Scholar
• Trowbridge R, Dugan W, Jay SJ et al. Determining the effectiveness of a clinical-practice intervention in improving the control of pain in outpatients with cancer. Acad. Med.72(9), 798–800 (1997).
   PubMed Web of Science ®Google Scholar
• Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol.14(6), 1756–1764 (1996).
   PubMed Web of Science ®Google Scholar
• Doyle C, Crump M, Pintilie M, Oza AM. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J. Clin. Oncol.19(5), 1266–1274 (2001).
   PubMed Web of Science ®Google Scholar
• Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur. J. Cancer33(Suppl. 1), S18–S22 (1997).
   Google Scholar
• Langendijk JA, Aaronson NK, de Jong JM et al. Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer. J. Clin. Oncol.19(8), 2123–2133 (2001).
   PubMedGoogle Scholar
• Kelly JF, Delclos ME, Morice RC, Huaringa A, Allen PK, Komaki R. High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: the 10-year M. D. Anderson Cancer Center experience. Int. J. Radiat. Oncol. Biol. Phys.48(3), 697–702 (2000).
   PubMedGoogle Scholar
• Bruner DW, Bryan CJ, Aaronson N et al. Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J. Clin. Oncol.25(32), 5051–5057 (2007).
   PubMed Web of Science ®Google Scholar
• Brundage M, Osoba D, Bezjak A, Tu D, Palmer M, Pater J. Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.25(32), 5078–5081 (2007).
   PubMed Web of Science ®Google Scholar
• Osoba D, Bezjak A, Brundage M, Pater J, National Cancer Institute of Canada Clinical Trials Group. Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group experience. Value Health10(Suppl.) 45 (2007).
   Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst.85(5), 365–376 (1993).
   PubMed Web of Science ®Google Scholar
• Osoba D, Aaronson N, Zee B, Sprangers M, Te VA. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group. Qual. Life Res.6(2), 103–108 (1997).
   PubMedGoogle Scholar
• Osoba D. The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: organization and functions. Qual. Life Res.1(3), 211–218 (1992).
   PubMedGoogle Scholar
• Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L. Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.15(1), 116–123 (1997).
   PubMed Web of Science ®Google Scholar
• Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med. Care41(5), 582–592 (2003).
   PubMed Web of Science ®Google Scholar
• Osoba D, Bezjak A, Brundage M et al. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur. J. Cancer41(2), 280–287 (2005).
   PubMed Web of Science ®Google Scholar
• Bezjak A, Dixon P, Brundage M et al. Randomized Phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer. Int. J. Radiat. Oncol. Biol. Phys.54(3), 719–728 (2003).
   Google Scholar
• Bleehen NM. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Br. J. Cancer65, 934–941 (1992).
   PubMed Web of Science ®Google Scholar
• Hardy JR, Noble T, Smith IE. Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br. J. Cancer60(5), 764–766 (1989).
   PubMedGoogle Scholar
• Higginson I, McCarthy M. Measuring symptoms in terminal cancer: are pain and dyspnoea controlled? J. R. Soc. Med.82(5), 264–267 (1989).
   PubMed Web of Science ®Google Scholar
• Fairclough DL, Gagnon DD, Zagari MJ, Marschner N, Dicato M. Evaluation of quality of life in a clinical trial with non-random dropout: the effect of epoetin alfa in anemic cancer patients. Qual. Life Res.12(8), 1013–1027 (2003).
   PubMed Web of Science ®Google Scholar
• Fairclough DL, Peterson HF, Chang V. Why are missing quality of life data a problem in clinical trials of cancer therapy? Stat. Med.17(5–7), 667–677 (1998).
   PubMed Web of Science ®Google Scholar
• Hopwood P. Quality of life assessment in chemotherapy trials for non-small cell lung cancer: are theory and practice significantly different? Semin. Oncol.23(5 Suppl.10), 60–64 (1996).
   PubMed Web of Science ®Google Scholar
• Fitzsimmons D, Johnson CD. Quality of life after treatment of pancreatic cancer. Langenbecks Arch. Surg.383(2), 145–151 (1998).
   PubMedGoogle Scholar
• Kaasa S. Using quality of life assessment methods in patients with advanced cancer: a clinical perspective. Eur. J. Cancer31A(Suppl. 6), S15–S17 (1995).
   PubMedGoogle Scholar
• Tannock IF. New perspectives in combined radiotherapy and chemotherapy treatment. Lung Cancer10(Suppl. 1), S29–S51 (1994).
   PubMed Web of Science ®Google Scholar
• Kaasa S, Bjordal K, Aaronson N et al. The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur. J. Cancer31A(13–14), 2260–2263 (1995).
   PubMed Web of Science ®Google Scholar
• Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J. Clin. Oncol.16(1), 139–144 (1998).
   PubMed Web of Science ®Google Scholar
• Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med. Care41, 582–592 (2003).
   PubMed Web of Science ®Google Scholar
• Barnes EA, Palmer JL, Bruera E. Prevalence of symptom control and palliative care abstracts presented at the annual meeting of the American Society for Therapeutic Radiology and Oncology. Int. J. Radiat. Oncol. Biol. Phys.54(1), 211–214 (2002).
   PubMedGoogle Scholar
• Fairclough DL, Peterson HF, Cella D, Bonomi P. Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Stat. Med.17(5–7), 781–796 (1998).
   PubMed Web of Science ®Google Scholar
• Fayers PM, Jones DR. Measuring and analysing quality of life in cancer clinical trials: a review. Stat. Med.2, 429–446 (1983).
   PubMedGoogle Scholar
• Quality of Life: Assessment, Analysis and Interpretation. Fayers PM, Machin D (Eds). John Wiley & Sons Ltd, NY, USA (2000).
   Google Scholar
• Cella D, Gershon R, Lai JS, Choi S. The future of outcomes measurement: item banking, tailored short-forms, and computerized adaptive assessment. Qual. Life Res.16(Suppl.), 41 (2007).
   PubMedGoogle Scholar
• Cella D, Yount S, Rothrock N et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med. Care45(5 Suppl. 1) S11 (2007).
   Google Scholar
• Langendijk JA, ten Velde GP, Aaronson NK, de Jong JM, Muller MJ, Wouters EF. Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study. Int. J. Radiat. Oncol. Biol. Phys.47(1), 149–155 (2000).
   PubMedGoogle Scholar
• Chow E, Wu JS, Hoskin P, Coia LR, Bentzen SM, Blitzer PH. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother. Oncol.64(3), 275–280 (2002).
   PubMed Web of Science ®Google Scholar
• Lee CW, Chi KN. The standard of reporting of health-related quality of life in clinical cancer trials. J. Clin. Epidemiol.53(5), 451–458 (2000).
   PubMed Web of Science ®Google Scholar
• Sprangers MA. Quality-of-life assessment in oncology. Acheivements and challenges. Acta Oncol.41(3), 229–237 (2002).
   PubMed Web of Science ®Google Scholar
• Sprangers MA. Response-shift bias: a challenge to the assessment of patients’ quality of life in cancer clinical trials. Cancer Treat. Rev.22(Suppl. A), 55–62 (1996).
   PubMed Web of Science ®Google Scholar
• Sprangers MA, Moinpour CM, Moynihan TJ, Patrick DL, Revicki DA. Assessing meaningful change in quality of life over time: a users’ guide for clinicians. Mayo Clin. Proc.77(6), 561–571 (2002).
   PubMed Web of Science ®Google Scholar
• Brundage M, Feldman-Stewart D, Leis A et al. Communicating quality of life information to cancer patients: a study of six presentation formats. J. Clin. Oncol.23(28), 6949–6956 (2005).
   PubMedGoogle Scholar